Posts by Mourabit Halima

In recent years, growing understanding of the structural and immune microenvironmental features of hepatocellular carcinoma (HCC) has placed immunotherapy at the forefront of HCC research and treatment. The emergence of immune checkpoint inhibitors (ICIs) and adoptive cell therapy (ACT) has opened new avenues of hope for patients with HCC. ACT, in particular, is a promising approach that involves the infusion of ex vivo activated and expanded autologous or allogeneic immune effector cells, and has shown potential in the treatment of infections, autoimmune disorders, and malignancies.

Hepatocellular carcinoma (HCC) is a major global health burden and a leading cause of cancer-related mortality. Curative hepatectomy is often not feasible due to advanced disease or insufficient liver function. Transarterial chemoembolization (TACE) remains the standard treatment for patients in the intermediate stage, and in some guidelines, even for advanced stages. However, the landscape has evolved with the introduction of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs). While these therapies have shown clinical efficacy individually or in dual combinations, the benefit of combining all three modalities—TACE, TKIs, and ICIs—as a "triple conversion therapy" had not been validated in large, real-world cohorts until the GUIDANCE001 study.

Editor’s Note At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the ANCHOR study, led by Professor Kefeng Ding from the Second Affiliated Hospital of Zhejiang University School of Medicine, was presented as a Late-Breaking Abstract (LBA), marking a significant breakthrough in the treatment landscape of advanced colorectal cancer.

Editor’s Note At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, three high-impact studies targeting KRAS G12C-mutant colorectal cancer (CRC) revealed groundbreaking progress in precision oncology. KRAS G12C is a notoriously difficult-to-treat molecular subtype of CRC, historically plagued by limited therapeutic options. However, the presentation of data from the CodeBreaK 101 study, a Phase I/II trial of olomorasib combined with cetuximab, and the KANDLELIT-001 trial has brought new hope to the field.

Editor’s Note: A deep understanding of the dynamic changes within the tumor microenvironment is crucial to accurately assess treatment response and disease progression in cancer patients. At the 2025 ASCO…

Nasopharyngeal carcinoma (NPC) is a malignancy with high prevalence in Southern China and other Southeast Asian countries, imposing a significant disease burden. Treatment options for recurrent/metastatic NPC (R/M NPC) remain limited. In recent years, immune checkpoint inhibitors (ICIs) have brought new hope to this patient population, and domestically developed ICIs in China have demonstrated promising efficacy.

In celebration of the 2025 National Science and Technology Workers Day and International Children’s Day, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College hosted a public science outreach event as part of the National Open Day at the National Key Laboratory of Hematology and Health. Over 200 primary and secondary school students from Tianjin, accompanied by their parents, participated in the event. The Deputy Director of Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Dr. Xiaoli Liu, delivered opening remarks, and the event was chaired by Mr. Chuan Wang, Director of the Education Office.

Editor’s Note: The 2025 ASCO Annual Meeting is currently in full swing across the Pacific, and several China-led clinical studies in breast cancer have captured significant international attention. Among them,…

Editor's Note: At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the ANCHOR study, led by Professor Kefeng Ding from The Second Affiliated Hospital Zhejiang University School of…

&t=47s